These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 30517603)

  • 61. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
    Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD
    Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of palivizumab prophylaxis on respiratory syncytial virus-associated hospitalizations in infants with congenital diaphragmatic hernia.
    Shao PL
    Pediatr Neonatol; 2018 Apr; 59(2):111. PubMed ID: 29551617
    [No Abstract]   [Full Text] [Related]  

  • 64. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
    Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
    Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study.
    Kamori A; Morooka Y; Yamamura K; Chong PF; Kuga N; Takahata Y; Sagawa K; Furuno K
    Medicine (Baltimore); 2021 Nov; 100(47):e27952. PubMed ID: 34964779
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
    J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
    Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
    J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia.
    Masumoto K; Nagata K; Uesugi T; Yamada T; Kinjo T; Hikino S; Hara T; Taguchi T
    Pediatr Int; 2008 Aug; 50(4):459-63. PubMed ID: 19143967
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CARESS: the Canadian registry of palivizumab.
    Mitchell I; Paes BA; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2011 Aug; 30(8):651-5. PubMed ID: 21343842
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
    Feltes TF; Sondheimer HM
    Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
    Winterstein AG; Eworuke E; Xu D; Schuler P
    Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
    Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
    Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study.
    Sheridan-Pereira M; Murphy J; Sloan J; Crispino G; Leahy A; Corcoran JD; Dempsey E; Elnazir B; Gavin P; Sharif F; Gul R; Satas S; Murphy J; Gormally S; Shanaa I; Waldron D; Mc Mahon P; Carson J; Blanken M; Bont L; Paes B
    Pediatr Infect Dis J; 2016 Jan; 35(1):19-24. PubMed ID: 26379160
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro.
    Lekic E; Dragas L; Nikcevic D; Lekic J; Dedic A; Sulovic L
    Turk J Pediatr; 2024 May; 66(2):161-170. PubMed ID: 38814297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.